Greenwich LifeSciences, Inc.
greenwichlifesciences.comAI Executive Summary
AI-powered analysis of 10-Q filing content
Greenwich LifeSciences shows severe deterioration with Q1 2026 losses doubling to $5.7M vs $2.7M in Q1 2025, driven by R&D spending surge to $5.2M. Despite raising $9M through equity sales, the company remains pre-revenue with accelerating cash burn and continued dilution of shareholders.
Red Flags Detected (6)
Net losses doubled year-over-year from $2.7M to $5.7M in Q1
R&D expenses increased 129% to $5.2M indicating escalating development costs
Zero revenue despite being in clinical stage development
3 more red flags detected
Key Takeaways
Company is in intensive clinical development phase with dramatically increased spending
Current cash of $10.5M provides approximately 2 quarters of runway at current burn rate
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.